---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117116"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-22T00:05:10.699887+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q3 revenue down 18% to $16.1M; net loss $10.1M; DFD-29 Phase 3 75% enrolled

## Summary
- Revenue $16.1M in Q3 2022 versus $19.6M in Q3 2021, decline due to Targadox generic competition.
- Net loss $10.1M ($0.57/sh) vs $10.6M ($1.16/sh); Non-GAAP Adj EBITDA loss $4.0M vs +$1.3M.
- DFD-29 Phase 3 studies 75% enrolled; top-line data expected H1 2023, NDA filing H2 2023.
- Nine-month revenue up 26% to $57.7M; CEO expects record full-year 2022 revenue.
- Company expects to launch another product in the upcoming months.

## SEC filing metadata
- accession: 0001104659-22-117116
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465922117116/0001104659-22-117116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465922117116/tm2230077d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117116
- JSON: https://secwatch.observer/filing/0001104659-22-117116.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117116.txt

## Key facts
- Earnings Releases
  Journey Medical Corp reported the third quarter and nine months ended September 30, 2022 results: revenue $16.1 million, net income ($10.1) million, EPS ($0.57) per share basic and diluted.
  - Period: the third quarter and nine months ended September 30, 2022
  - Revenue: $16.1 million
  - Net income: ($10.1) million
  - EPS: ($0.57) per share basic and diluted
  - Result: reported results
  source text: position Journey Medical for sales growth in the coming years. Journey Medical also expects to launch another product in the upcoming months.” Financial Results: · Revenues were $16.1 million for the third quarter of 2022, compared to revenues of $19.6 million for the third quarter of 2021, representing a decline of $3.5 million. The decline in revenue was
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867066/000110465922117116/0001104659-22-117116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.